Healthcare Professional (HCP) Perspectives
As noted in Part 1 and Part 2 blogs in this series, successful compliance ultimately involves everyone in the organization and also includes engaging HCPs in the process. Everyone has the responsibility for doing the right thing, and organizational culture must support and strengthen this process. Operational checklists and audit practices are all important, along with a universal understanding of what is meant by compliance. Everyone that compliance touches should be ready to step up and do their part to ensure success.
Consider that the average length of time it takes to develop a new medicine or product ranges from 10 to 15 years. During this time, Life Sciences employees in many areas interact with HCPs. Throughout this interval, each organization needs to ensure that every action and interaction is compliant across state, federal, and even international regulations, as well as internal corporate guidelines and SOPs. The expectation that everyone is responsible for ethical practices and standards begs the question: How can HCPs contribute to increased success with compliance for an organization while simultaneously focusing on patient needs? At AHM’s Annual Industry Conference, our HCP panelists commented on this very question. Some of their suggestions included:
- “Just make complying easier!”
- “We need time with our patients, we need time in the office, we need time to keep abreast of cutting edge therapies—you need to make dealing with industry less cumbersome.”
We recommend that Life Science organizations start by communicating the compliance process to HCP in a clear, concise, and continuous manner. This should include providing any rules or policies around reporting or exceptions to the process. The feedback that AHM received implies that this is still not adequately addressed. When all parties are engaged and informed, a solid relationship is built between the parties, and the credibility of the organization is increased. HCPs long to be communicated to correctly and clearly. To make their experience less confusing and burdensome, they would like to have the same experiences regardless of what activity or who in the organization they are working with. Since the Open Payments Act was established, HCPs and their relationships with industry are reportable, thereby providing greater transparency into financial transfers of value in categories of honoraria, and travel and meal costs associated with speaking or consulting. HCPs contribute to compliance by understanding the policies of the organizations they interact with. Moreover, HCPs have welcomed the communication necessary to inform the public on their role in the drug/device development process and how it impacts patients and their care.
HCPs partner with industry to achieve their primary goal, patient care; however, the process can be further improved so that compliance obstacles do not stand in the way.
AHM has a suite of end-to-end single-platform solutions to meet the compliance needs of Life Sciences organizations and HCPs. These capabilities can smooth compliance for HCPs and help them become a valuable partner in the process. For more information, please visit: http://www.ahmdirect.com/.
Lisa Keilty, Global VP of Compliance and Strategic Solutions, AHM
Lisa joined AHM after serving as founder of the Compliance Consulting firm PMC2 and spending over 26 years in the life sciences and meeting management industry. Leading such organizations as Pfizer, Bristol Myers Squibb and Biogen Idec through numerous international projects, financial transparency and reporting requirements, Lisa’s industry expertise has saved Life Sciences and Meeting Management organizations over 30 million dollars. As a member of the Business Development team, Lisa’s primary focus will be Thought Leadership, Demand Generation and Solution Design.